HOW TO READ DATA
The interactive data visualizer showcases some of the biggest M&A deals from the 2000s onward. However, it is important to note that some other significant M&A events may not have been included due to various reasons such as M&A involving the acquisition of non-operational units or incomplete data availability.
Some of the M&A deals included in the visualizer are highly complex in nature and involve several companies intertwining and assuming each other's names. In some cases, the clinicaltrials.gov database was retrospectively changed such that the originally recorded sponsor company name has been changed to the acquirer's name without any audit trail, and in some cases not updated properly. Therefore, a statistical consideration has been taken where the number of clinical trials run by some acquired companies has been artificially zeroed out at the time of the M&A deal and added to the number of clinical trials run by the acquiring company. The justification for such consideration is that the acquiring company assumes all legal and financial rights and liabilities associated with the trials as shown in their balance sheet.
Johnson & Johnson and Janssen are represented as a single entry in the visualizer despite being two legal entities. This is because J&J is the sole owner of Janssen, which is a key player in running clinical trials.
It is important to note that in 2015, Actavis acquired Allergan but kept the name Allergan. Subsequently, Allergan divided its operations into Allergan Generics and Allergan plc. In 2016, Teva Pharmaceutical acquired Allergan Generics, and in 2020, AbbVie acquired Allergan plc.
The "stock prices" displayed in the visualizer refer to historical, daily, and close stock prices acquired from finance.yahoo.com for periods 1 year prior and 3 years after the M&A event. This has been done mainly to demonstrate the impact of the M&A on the stock prices.
The "R&D spending" displayed in the visualizer excludes IPR&D (operational R&D cost assumed from buying another company's clinical research portfolio). The data for R&D spending was acquired through sec.gov. This has been done mainly to demonstrate the impact of the M&A on the acquirer R&D spending.
Due to incomplete data availability, share price and R&D data for Shire company may not be complete or available.
The variables displayed in the last graph of the visualizer can be opted-out by a single click or singled out by a double-click for easier analysis.
Some of the M&A deals included in the visualizer are highly complex in nature and involve several companies intertwining and assuming each other's names. In some cases, the clinicaltrials.gov database was retrospectively changed such that the originally recorded sponsor company name has been changed to the acquirer's name without any audit trail, and in some cases not updated properly. Therefore, a statistical consideration has been taken where the number of clinical trials run by some acquired companies has been artificially zeroed out at the time of the M&A deal and added to the number of clinical trials run by the acquiring company. The justification for such consideration is that the acquiring company assumes all legal and financial rights and liabilities associated with the trials as shown in their balance sheet.
Johnson & Johnson and Janssen are represented as a single entry in the visualizer despite being two legal entities. This is because J&J is the sole owner of Janssen, which is a key player in running clinical trials.
It is important to note that in 2015, Actavis acquired Allergan but kept the name Allergan. Subsequently, Allergan divided its operations into Allergan Generics and Allergan plc. In 2016, Teva Pharmaceutical acquired Allergan Generics, and in 2020, AbbVie acquired Allergan plc.
The "stock prices" displayed in the visualizer refer to historical, daily, and close stock prices acquired from finance.yahoo.com for periods 1 year prior and 3 years after the M&A event. This has been done mainly to demonstrate the impact of the M&A on the stock prices.
The "R&D spending" displayed in the visualizer excludes IPR&D (operational R&D cost assumed from buying another company's clinical research portfolio). The data for R&D spending was acquired through sec.gov. This has been done mainly to demonstrate the impact of the M&A on the acquirer R&D spending.
Due to incomplete data availability, share price and R&D data for Shire company may not be complete or available.
The variables displayed in the last graph of the visualizer can be opted-out by a single click or singled out by a double-click for easier analysis.